Tag Archives: announcement

RESI on MaRS Panel Announcement: Corporate Venture Capital

22 Mar

By Cole Bunn, Director of Research, LSN

cole-wp

Large corporations, especially in the pharmaceutical and biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation – an exit partner. However, attracting and concentrating talent, and providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the third time as a part of the Toronto Health Innovation Week and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests, and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by Salim Teja, President, Venture Services, MaRS Discovery District, this panel will feature:

  • Marian Nakada, VP of Venture Investing, Johnson & Johnson
  • Jens Eckstein, President, SR One
  • Richard Osborn, Managing Partner, TELUS Ventures
  • Tom Gibbs, Director, Debiopharm Innovation Fund

By registering for RESI on MaRS, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

RESI on MaRS Panel Announcement: Medical Device Investors

22 Mar

By Lucy Parkinson, VP of Investor Research, LSN

Medical device innovation is known for being a challenging area for raising capital.  Given the timelines and capital requirements involved, as well as the increasing consolidation of the major firms that make up the exit landscape for devices, entrepreneurs may find it difficult to build their investment story.  However, LSN is in contact with hundreds of investors who are seeking deals in the device space, either for purely return-driven investments or for adding to a strategic pipeline.  At RESI, we aim to bridge the gap between early stage device firms and investors and help entrepreneurs close those ‘last three feet’ to make deals.

At RESI on MaRS, we welcome a Medical Device Investors panel featuring experienced investors from across North America, including both strategic players and financially-driven venture investors who will explore and elucidate the world of early stage device investment from every angle.  The panel will be moderated by Sam Ifergan, President & CEO, iGan Partners, and the participants are:

  • Katherine Parra Moreno, Vice President of Business Development, Epic Capital Management
  • Zishan Haroon, Chairman and General Partner, Julz Co LLC
  • V Kadir Kadhiresan, Vice President, Venture Investments, Johnson & Johnson Innovation
  • Gerry Brunk, Managing Director, Lumira Capital

RESI San Francisco @ JPM Week – Medical Devices Panel Announcement

14 Dec

By Claire Jeong, Research Analyst, LSN

claire

With RESI San Francisco less than a month away, we are proud to announce the Medical Device investors panel, where 5 seasoned experts in medical device investments will discuss how they seek to work with early-stage medical technology entrepreneurs.

The fundraising process and path to commercialization for medical device products continue to be a rigorous challenge for many budding companies. Especially with the exponential growth of the IoT/IoMT market, a growing number of entrepreneurs are focusing on the development of connected, “smarter” devices that incorporate a software or data component. Although often overshadowed by the biopharmaceutical industry in terms of degree of need or financial returns, the medical device sector is a very much needed area in the improvement of healthcare.

If you are a medical device entrepreneur and heading to San Francisco for JPM week, you do not want to miss out on our RESI Medical Devices panel! Our panelists are:

  • Renee Ryan, Vice President, JJDC, Johnson & Johnson Innovation (JLABS)
  • Yao Li Ho, Director of Business Development, LYFE Capital
  • Zishan “Z” Haroon, Chairman & General Partner, Julz Co LLC
  • Sam Ifergan, President & CEO, iGan Partners
  • Randy Scott, Partner, HealthQuest Capital

RESI NYC 2017 Innovation Challenge – Winners Announced

16 Nov

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-newYesterday, we held the Redefining Early Stage Investments (RESI) conference in New York for the first time, and 36 finalists competed for “investment” tokens from the RESI audience. These finalists included companies developing novel drugs or devices, new diagnostics and healthcare IT applications. All of these companies have the potential to revolutionize medicine, but there could only be 3 top prize winners.

First Place: Sen-Jam Pharma

Sen-Jam Pharmaceutical is reimaging health through innovation. Sen-Jam’s Exulta™ asset, a fixed-dose novel combination therapy, provides opioid free pain relief with GI protection for extended use. Exulta™ can stabilize the innate immune system by modulating histamines, prostaglandins and regulating pro-inflammatory cytokines. Exulta™ can also attenuate glial cell activity. Exulta’s platform can be used for multiple indications: reducing opioid induced hyperalgesia, tolerance and dependence for all chronic opioid users, reducing symptoms of opioid withdrawal, treatment of arthritis, reducing common cold symptoms, reducing alcohol hangover symptoms, and preventing symptoms associated with vaccine administration. Exulta™ has been shown in volunteers to reduce symptoms associated with the innate immune response by 60-90% in over 500 dosing events without adverse effects.

Jim Iversen, CEO & COO, Sen-Jam Pharmaceutical | Natasha Eldridge, Director of RESI Conference Series, LSN | Thomas Dahl, Head of Product Development & Regulatory Affairs, Sen-Jam Pharmaceutical | Lucy Parkinson, Director of Investor Research, LSN

Second Place: Bioharmony Therapeutics

Bioharmony Therapeutics is an early-stage biotechnology company developing next-gen antimicrobial therapies for lethal drug-resistant bacterial infections. We are exploiting millions of year of phage-bacteria evolution to develop lysins, enzymes produced by phages that rapidly kill bacteria and have a very low chance of developing resistance. Our lead product targets infections caused by Acinetobacter baumannii, a MDR-pathogen that poses the greatest threat to human health. Our pipeline targets infections caused by other Gram-negative bacteria such as E.coli and Klebsiella, for use in UTI, pneumonia and sepsis.

Chandrabali Ghose, Founder & CEO, Bioharmony Therapeutics | Natasha Eldridge, Director of RESI Conference Series, LSN | Lucy Parkinson, Director of Investor Research, LSN

Third Place: Mirimus

Mirimus is engaged in the design, development and pioneering of new genome editing technologies to develop animal models that are crucial for the preclinical evaluation of new therapeutics. We are a high-tech business unlike any other with expertise in RNAi technologies critical for development of animal models that can pave the way we develop drugs, by pin-pointing potential toxicities and guiding the development of safer, more effective therapeutics. We are revolutionizing the creation of animal models by synergzing RNAi and CRISPR/Cas9 technologies for development of mice, rats and higher organisms.

Prem Premsrirut, Founder & CEO, Mirimus | Lucy Parkinson, Director of Investor Research, LSN | Natasha Eldridge, Director of RESI Conference Series, LSN

If you missed out on the opportunity to compete in the RESI NYC Innovation Challenge, we’d be happy to take your application for our upcoming San Francisco event on January 9th.

Apply for RESI San Francisco 2018 Innovation Challenge Now!

RESI New York City: Venture Philanthropy Panel Announcement

2 Nov

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Venture philanthropic foundations have deep expertise that is often overlooked. Each foundation has a specific, genuine mission towards a disease area that provides them enormous capacity to bring forward more than any entrepreneur can realize. Along with funding, venture philanthropic investors can provide patient access for underserved populations, specialize in assessing and tracking “positively impactful” technology in their particular field, and utilize their own relationships with traditional ventures in creative ways, among other initiatives.

New York City is home to a great number of life science foundations. LSN has dedicated the Venture Philanthropy panel to the following five incredible Foundations for the RESI New York City Conference on November 15th. Moderated by John Walter, CEO and President of Alliance for Cancer Gene Therapy, the audience will have an exclusive opportunity to hear from:

  • Alyssa Reimer, Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson’s Research
  • Michael Batten, Director, Strategic Partnerships, Juvenile Diabetes Research Foundation (JDRF) T1D Fund
  • Ken LaMontagne, VP of Research, Therapy Acceleration Program, Leukemia & Lymphoma Society
  • Andres Hurtado-Lorenzo, Director of Translational Research, Crohn’s and Colitis Foundation

Venture philanthropy investors maintain the genuine purpose of moving forward in the field of life science. Non-traditional investors such as these groups are great funding sources with incredible knowledge in their fields, while also taking inspirational strides to achieve their goals.

Foundations are a strong reminder not to lose track of the mission in life science.

Register before it’s too late to hear first-hand from this fantastic panel!

RESI Boston 2017 Innovation Challenge – Winners Announced NYC Application is Now Open

28 Sep

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-newOn Tuesday September 26th, RESI Boston was host to the largest RESI Innovation Challenge yet, with 40 companies competing for the “investment” votes of their fellow attendees. These innovative startups came from across the life science spectrum – develop ing novel products in biotech, medtech, diagnostics and healthcare IT, with the aim of addressing a wide range of different diseases. We hope that all will succeed in bringing their products to patients, but there could only be 3 prize winners. Without further ado, LSN would like to present the top three competitors:

First Place: Wellesley Pharmaceuticals

Nocturia, the frequent need to urinate at night, afflicts 2.3B people, causing insomnia, fatigue, depression, and lower quality of life. It leads to higher rates of heart disease, stroke, brain damage, and deadly falls, killing thousands daily. Wellesley’s Phase 2 trial ended 9/8/17. Results will be unblinded 10/2, but 50% of patients reported >25% nocturia reduction and 27% reported 40-96% benefits, with no side effects. 25% took placebo and 25% reported results averaging 0%. OAB drugs offer 10-15% benefits, bad side effects, and sell $2B/year! Licensing dozens of worldwide patents to big pharma comes next. We expect $10M upfront and 15% of revenue, while they take over all future costs, before launching our drug worldwide. Net margins should approach 95%.

Michael Quigley, VP of Investor Research, Life Science Nation | David Dill, CEO, Wellesley Pharmaceuticals | Dennis Ford, CEO, Life Science Nation

Second Place: Molecular Targeting Technologies

Molecular Targeting Technologies, Inc.’s (MTTI) TDURA is an imaging agent with a unique mechanism to “see” cell death. It is fast, sensitive and enables actionable tracking of cell damage, reducing toxicity,improving survival and minimizing healthcare costs. MTTI has demonstrated proof of efficacy in cardiotoxicity and oncology models. TDURA detected chemotherapy related cardiac dysfunction prior to existing technologies, detected tumor response to therapy as early as 1 day and distinguished responders from non-responders. TDURA is ready for clinical development. Phase II approval for the first indication is projected in 2022. Exit prior to phase III should deliver ≥$100 million value. MTTI has an experienced team, a strong IP and an innovative platform with multiple indications targeted to several unmet medical needs.

Michael Quigley, VP of Investor Research, Life Science Nation | Koon Yan “Chris” Pak, Co-Founder & CEO, Molecular Targeting Technologies, Inc. | Michael Silvon, Senior Vice President of Business Development, Molecular Targeting Technologies, Inc. | Dennis Ford, CEO, Life Science Nation

Third Place: RPS Diagnostics

RPS DIAGNOSTICS is developing FebriDx® for launch outside the USA in 2018. FebriDx is the first and only rapid, in-office test that uses a fingerstick blood sample to help differentiate viral from bacterial acute febrile respiratory infection. The FebriDx® test can be used to help triage infectious patients at the point of care, providing clinicians with a clear path to diagnosis and treatment, leading to more efficacious healthcare decisions. Test results are available in 15 minutes, allowing for an effective treatment plan to be established during the patient’s initial office visit.

Michael Quigley, VP of Investor Research, Life Science Nation | Dennis Ford, CEO, Life Science Nation | Doug Lawrence, CEO, RPS Diagnostics

Thank you to all who competed in the RESI Boston Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

Apply for RESI NYC Innovation Challenge Now!

RESI San Diego 2017 Innovation Challenge – Winners Announced

22 Jun

By Nono Hu, Director of Marketing, LSN

On June 19, more than 600 healthcare entrepreneurs and investors entered the exhibition hall at the Westin San Diego Gaslamp Quarter. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Taithera

Taithera is redefining orthopaedics. Taithera is developing a first-in-class bone targeted drug delivery platform for the treatment of musculoskeletal disorders. The core of Taithera’s revolutionary platform is a nanoparticle that is programmed to deliver therapeutics directly to the site of a bone lesion. This hyper-targeted delivery platform can be used to treat primary and metastatic bone cancers, fractures, osteoporosis, and other bone conditions. Taithera is based in New York City, and was founded by Mo Chen, PhD and Seth Harlem.

Michael Quigley, VP of Market Research, Life Science Nation | Mo Chen, Co-Founder & Chief Science Officer, Taithera | Seth Harlem, Co-Founder & Chief Executive Officer, Taithera

Second Place: Tasso

Tasso is a medical device company that is developing the HemoLink, a user-friendly way to self-collect blood for clinical testing that has the potential to fundamentally change how people interface with healthcare. The HemoLink is a device that enables high-quality blood sample collection with one press of a button. After the blood draw is complete, the tube appended to the device simply twists off and can be used directly within standard lab processes. The HemoLink is enabled by novel microfluidic technologies that enable connectivity (e.g. tube types), simple low-cost manufacturing, and plasma separation onsite. The HemoLink can replace phlebotomy in small clinics and bring blood collection to the home.

Michael Quigley, VP of Market Research, Life Science Nation | Ben Casaavant, VP, Engineering, Tasso

Third Place: ViewsIQ

ViewsIQ is a medical technology company, digitizing patient samples microscopically to disrupt the pathology practice – the last remaining medical imaging field to go digital. ViewsIQ’s Panoptiq system is the first software-based approach to digital imaging that allows seamless integration into a Pathologist’s clinical workflow. With Panoptiq, the cost barrier to digital imaging has been removed, permitting clinicians to offer expert diagnostic care to patients virtually anywhere in the world.

Michael Quigley, VP of Market Research, Life Science Nation | Herman Lo, CEO, ViewsIQ

Thank you to all who competed in the RESI San Diego Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

%d bloggers like this: